The importance of HLA DRB1 gene allele to clinical features and disability in patients with multiple sclerosis in Lithuania

BMC Neurology

Volumn 13, Issue , 2013, Pages

  Balnyte, Renata ^a   Rastenyte, Daiva ^a   Vaitkus, Antanas ^a   Mickeviciene, Dalia ^a   Skrodeniene, Erika ^a   Vitkauskiene, Astra ^a   Uloziene, Ingrida ^a  

^a LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DRB1 ANTIGEN; OLIGOCLONAL BAND;

ADULT; AGE; ALLELE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL FEATURE; CLINICAL TRIAL; DISABILITY; DISEASE COURSE; DISEASE DURATION; FEMALE; GENOTYPE; HUMAN; LITHUANIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; RECURRENCE RISK;

ADULT; DISABLED PERSONS; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, VISUAL; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA-DRB1 CHAINS; HUMANS; LITHUANIA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OLIGOCLONAL BANDS; PHOTIC STIMULATION; STATISTICS, NONPARAMETRIC;

EID: 84880011482     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-13-77     Document Type: Article

References (30)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000, 343:938-952. 10.1056/NEJM200009283431307, 11006371.
2. Ramagopalan VS, Dobson R, Meier CU, Giovannoni G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol 2010, 9:727-739. 10.1016/S1474-4422(10)70094-6, 20610348.
3. Ramagopalan VS, Ebers GC. Multiple sclerosis: major histocompatibility complexity and antigen presentation. Genome Med 2009, 1:105-108. 10.1186/gm105, 2808740, 19895714.
4. Oksenberg RJ, Baranzini ES. Multiple sclerosis genetics- is the glass half full, or half empty?. Nat Rev Neurol 2010, 6:429-437. 10.1038/nrneurol.2010.91, 20625377.
5. Romeiro-Pinel L, Pujal JM, Martinez-Yelamos S, Gubierias L, Matas E, Bau L. HLA-DRB1: genetic susceptibility and disability progression in a Spanish multiple sclerosis population. Eur J Neurol 2011, 18:337-342. 10.1111/j.1468-1331.2010.03148.x, 20629714.
6. Smestad C, Brynedal B, Jonasdottir G, Lorentzen AR, Masterman T, Akesson E, et al. The impact of the HLA-A and -DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients. Eur J Neurol 2007, 14:835-840. 10.1111/j.1468-1331.2007.01825.x, 17662002.
7. Weatherby SJM, Thomson W, Pepper L, Donn R, Worthington J, Mann CLA, et al. HLA DRB1 and disease outcome in multiple sclerosis. J Neurol 2001, 248:304-310. 10.1007/s004150170205, 11374095.
8. Hensiek AE, Sawcer SJ, Feakes R, Deans J, Mander A, Akesson E, et al. HLA-DR15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatry 2002, 72:184-187. 10.1136/jnnp.72.2.184, 1737743, 11796767.
9. Kouri I, Papakonstantinou S, Bempes V, Vasiliadis HS, Kyritsis AP, Pelidou HS. HLA associations with multiple sclerosis in Greece. J Neurol Sci 2011, 1-2:28-31.
10. Okuda DT, Srinivasan R, Oksenberg JR, Goodin DS, Baranzini SE, Beheshtian A, et al. Genotype-phenotype correlations in multiple sclerosis: HLA allele influence disease severity inferred by HMR spectroscopy and MRI measures. Brain 2009, 132:250-259. 2638695, 19022862.
11. Van der Walt A, Stankovich J, Bahlo M, Taylor BV, Van der Mei IAF, Foote SJ, et al. Heterogeneity at the HLA-DRB1 allelic variation locus does not influence multiple sclerosis disease severity, brain atrophy or cognition. Mult Scler 2011, 17:344-352. 10.1177/1352458510389101, 21149397.
12. World Health Organisation Multiple Sclerosis International Federation. Atlas Multiple Sclerosis resources in the world 2008 2008, Geneva: World Health Organisation, World Health Organisation.
13. Balnytė R, Rastenytė D, Mickevičienė D, Vaitkus A, Skrodenienė E, Vitkauskienė A. Frequency of HLA-DRB1 Gene Alleles in Patients With Multiple Sclerosis in a Lithuanian Population. Medicina (Kaunas) 2012, 1:9-14.
14. Polman CH, Reingold SC, Edan G. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald criteria. Ann Neurol 2005, 6:840-846.
15. Celesia GG, Brigell MG. Recommended standards for pattern electroretinograms and visual evoked potentials. Recommendations for the practice of clinical neurophysiology: guidelines of the International Federation of Clinical Physiology (EEG,suppl 52:45-52) 1999, Elsevier science, Deuschl G, Eisen A.
16. Siritho S, Freedman MS. The prognostic significance of cerebrospinal fluid in multiple sclerosis. J Neurol Sci 2009, 279:21-25. 10.1016/j.jns.2008.12.029, 19181345.
17. Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis. Arch Neurol 2005, 62:865-870. 10.1001/archneur.62.6.865, 15956157.
18. Olerup O, Zetterquist H. HLA-DRB typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992, 39:225-235. 10.1111/j.1399-0039.1992.tb01940.x, 1357775.
19. Silva AM, Pereira C, Bettencourt A, Carvalho C, Counto AR, Leite MI, et al. The role HLA-DRB* susceptibility and outcome of a Portuguese MS population. J Neurol 2007, 1-2:68-74.
20. Cree CAB, Reich ED, Khan O, De Jager PL, Nakashima I, Takahashi T, et al. Modification of multiple sclerosis phenotypes by African Ancestry at HLA. Arch Neurol 2009, 66:226-233. 10.1001/archneurol.2008.541, 19204159.
21. Stankovich J, Butzkueven H, Marriott M, Chapman C, Tubridy N, Tait BD, et al. HLA-DRB1 associations with disease susceptibility and clinical course in Australians with multiple sclerosis. Tissue Antigens 2009, 74:17-21. 10.1111/j.1399-0039.2009.01262.x, 19392788.
22. Kučinskas V. Genetic diversity of population. Genetics 2001, 6:160-171.
23. Wu J-S, Qiu W, Castley A, James I, Mastaglia FL, Christiansen FT, et al. Modifying effects of HLA-DRB1 allele interactions on age at onset of multiple sclerosis in Western Australia. Mult Scler 2010, 16:15-20. 10.1177/1352458509350312, 19995849.
24. Barcellos LF, Sawcer S, Ramsay PP, Baranzini SE, Thompson G, Briggs F, et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet 2006, 18:2813-2824.
25. Matsuoka T, Matsushita T, Oseogawa M, Kawano Y, Minohara M, Mihara F, et al. Association of HLA DRB1 alleles with characteristic MRI features of Asian multiple sclerosis. Mult Scler 2008, 14:1181-1190. 10.1177/1352458508097818, 18952831.
26. Wu J-S, Qiu W, Castley A, James I, Joseph J, Christiansen FT, et al. Clinical profile and HLA-DRB1 genotype of late onset multiple sclerosis in Western Australia. J of Clinical Neuroscience 2010, 17:1009-1013.
27. Idiman E, Ozakbas S, Dogan Y, Kosehasanogullari G. The significance of oligoclonical bands in multiple sclerosis: relevance of demographic and clinical features, and immunogenetic backgrounds. J Neuroimmunol 2009, 212:121-124. 10.1016/j.jneuroim.2009.04.014, 19457560.
28. Romero-Pinel L, Yelamos-Martinez S, Bau L, Matas E, Guberias L, Maria Pujai J, et al. Association of HLA DRB1*15 allele and CSF oligoclonal bands in a Spanish multiple sclerosis cohort. Eur J Neurol 2011, 10:1258-1262.
29. Wu J-S, Qui W, Castley A, James I, Joseph J, Christiansen FT, et al. Presence of CSF oligoclonal bands is associated with the HLA-DRB1 genotype in a West Australian multiple sclerosis cohort. J Neuroimmunol 2010, 288:63-67.
30. Obermeier B, Mentele R, Malotka J, Kellermann J, Kumpfel T, Wekerle H, et al. Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat Med 2008, 14:688-693. 10.1038/nm1714, 18488038.